Search clinical trials for: Selumetinib capsule formulation

Total 4786 results

AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN (SPRINKLE)

Neurofibromatosis Type 1

United States, Spain, Germany, Netherlands, Russian Federation, Italy, Japan
AstraZeneca

Completed

A Study to Assess the Relative Bioavailability of 3 Different Formulations Under Fasted and Fed Condition

Chronic Kidney Disease

Germany
Forendo Pharma Ltd
Richmond Pharmacology Limited

Completed

A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations

Relative Bioavailability

United Kingdom
Lyndra Inc.

Terminated

Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects

Healthy | Gastric Retention

United Kingdom
Beijing Union Pharmaceutical Factory Ltd
R&G Pharma Studies Co.,Ltd.

Recruiting

Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD (BGFN-2022-02)

Generalized Anxiety Disorder

China
Eli Lilly and Company

Completed

A Study of Abemaciclib in Healthy Participants

Healthy

United States
Lyndra Inc.

Completed

Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules in Healthy Adults

Healthy | Gastric Retention

Australia
Shaheer A. Khan
AstraZeneca; Melanoma Research Alliance

Completed

Intermittent Selumetinib for Uveal Melanoma

Uveal Melanoma

United States
AstraZeneca

Completed

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects

Solid Tumors

United States
Intec Pharma Ltd.

Completed

Comparison of IN 10 003 to Placebo in Subjects With Insomnia Suffering From Difficulty in Falling Asleep and Staying Asleep

Subjects With Insomnia Suffering From Difficulty in Falling Asleep and Staying Asleep

Israel
Shanghai Jiao Tong University School of Medicine
Shanghai Chest Hospital

Recruiting

Limonene for Pulmonary Nodule Chemoprevention

Pulmonary Nodules

China
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

Infection, Human Immunodeficiency Virus | Infections, Human Immunodeficiency Virus and Herpesviridae

United States
Aragon Pharmaceuticals, Inc.

Completed

Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants

Healthy

United States
Chong Kun Dang Pharmaceutical

Completed

Study to Investigate the Effects of Food on the Pharmacokinetics/Pharmacodynamics of CKD-519

Healthy Volunteers

Korea, Republic of
Shire

Completed

Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Hadassah Medical Organization

Recruiting

Bioequivalence Assessment of Cannabidiol (CBD) Administrated in Oral Formulations

Pain

Israel
Reata, a wholly owned subsidiary of Biogen

Completed

RTA 408 Capsules in Patients With Melanoma - REVEAL

Melanoma | Unresectable (Stage III) Melanoma | Metastatic (Stage IV) Melanoma

United States
AstraZeneca

Completed

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers

Solid Tumours

United Kingdom
Reata, a wholly owned subsidiary of Biogen

Completed

Safety and PK/PD of RTA 1701 in Healthy Adults

Healthy

Australia
TaiGen Biotechnology Co., Ltd.

Completed

Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers

Healthy

United States
AstraZeneca

Completed

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

Healthy Volunteers Bioavailability Study

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Neurofibromatosis 1 (NF1) | Plexiform Neurofibromas (PN)

United States
AstraZeneca

Approved for marketing

An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

NF type1 With Inoperable Plexiform Neurofibromas

United States
AstraZeneca

Completed

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects

Solid Tumours

United States
Orion Corporation, Orion Pharma
Endo Pharmaceuticals

Completed

Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer (ARAFOR)

Prostate Cancer

Latvia
Hongsheng Tan
Shanghai Shen Kang Hospital Development Center; Longhua Hospital; Hongqiao International...

Completed

Limonene on Regulating Metabolism-related Fatty Liver Disease (MAFLD) and Analysis of TCM Constitution (DL-MAFLD-TCM)

Fatty Liver

China
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Neurofibromatosis Type 1

United States, Spain, Poland, Russian Federation
AstraZeneca

Withdrawn

Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study (PROTECT)

Neurofibromatosis Type 1 | Plexiform Neurofibromas | Post-operative

China
The Christie NHS Foundation Trust
AstraZeneca; University of Manchester

Completed

MEK Inhibitor and Thoracic Radiotherapy Trial (MEKRT)

Non Small Cell Lung Cancer

United Kingdom
Hillel Yaffe Medical Center

Unknown

Safety of Formalin-free Fixatives for In-Vivo Fixation of Skin Lesions.

Skin Abnormality

Israel
AstraZeneca

Completed

A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers

Healthy Volunteers Bioequivalence or Bioavailability Study

United Kingdom
Enzychem Lifesciences Corporation

Completed

EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation

Stomatitis

United States
Children's Hospital Medical Center, Cincinnati
AstraZeneca

Active, not recruiting

Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601)

Glioma | Ependymoma | Meningioma | Neurofibromatosis 2 | Vestibular Schwannoma

United States
Pfizer
Ono Pharmaceutical Co. Ltd; Pierre Fabre Laboratories

Completed

A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations (ERBA)

Healthy

United States
AstraZeneca

Completed

To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers

Solid Tumours

United States
Corcept Therapeutics

Completed

Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants

Healthy Adults

United Kingdom
Genzyme, a Sanofi Company

Completed

A Phase I Study of the Pharmacokinetic Variability and Relative Bioavailability of the Phase 3 and Common Blend Formulations of Eliglustat in Healthy Adult Subjects

Healthy Volunteer

United States
Tillotts Pharma AG
University Hospital, Basel, Switzerland; University of Basel; SocraTec R&D GmbH; Swiss Commission for Technology and Innovation

Completed

Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate Capsules

Healthy

Switzerland
Immunomolecular Therapeutics, Inc.
WCCT Global

Completed

Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes

Type1 Diabetes

United States
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)

Neurofibromatosis 1 | Plexiform Neurofibroma (PN)

United States, Canada, France, Italy, Germany, China, United Kingdom, Spain, Japan, Russian Federation, Australia, Poland, Brazil
OPKO Health, Inc.

Completed

Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)

Chronic Kidney Disease | Secondary Hyperparathyroidism | Vitamin D Insufficiency

United States
National Cancer Institute (NCI)

Active, not recruiting

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Non-Hodgkin Lymphoma | Refractory Primary Central Nervous System Neoplasm | Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma and other conditions

United States, Puerto Rico
Natrogen Therapeutics International, Inc

Unknown

Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis

Ulcerative Colitis

United States
Merck Sharp & Dohme LLC
AstraZeneca

Completed

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

Locally Advanced or Metastatic Solid Tumors
First Affiliated Hospital Xi'an Jiaotong University

Unknown

A Clinical Study on the Efficacy and Safety of the Treatment of Hyperplasia of Mammary Glands With Xiaoru Sanjie Capsule

Fibrocystic Disease of Breast

China
TaiRx, Inc.

Completed

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

Advanced Cancer

Taiwan
Psychiatric Hospital of the University of Basel

Terminated

Fecal Microbiota Transplantation in Depression

Major Depressive Disorder

Switzerland
National Cancer Institute (NCI)

Withdrawn

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Neoplasms, Nerve Tissue | Peripheral Nervous System Diseases | Heredodegenerative Disorders, Nervous System | Neurofibromatosis 1
Medtronic - MITG

Terminated

Feasibility Study to Evaluate the Performance of Flocculation-Adsorption System for Colon Cleansing Enhancement (RD-400)

Healthy

Israel
National Cancer Institute (NCI)

Completed

Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia

Myelodysplastic Syndromes | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Myelodysplastic/Myeloproliferative Neoplasms

United States

Search clinical trials for: Selumetinib capsule formulation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations